Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00314054 | Study Evaluating the Safety of HCV-796 in Subjects With Liver Disease and in Healthy Adults | PHASE1 | COMPLETED | 27 | — | — | May 1, 2006 | Oct 1, 2007 | Apr 14, 2008 | 3 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | HCV-796 1000mg single dose |
| Name | Type | Description |
|---|---|---|
| HCV-796 | DRUG | HCV-796 1000mg single dose |
Inclusion Criteria: * Men and women of non-childbearing potential. * Hepatic impairment subjects: Child-Pugh class A, B, or C according to the C-P classification based on history, physical examination, and laboratory test results. * Healthy volunteers: healthy as determined by the investigator. Ex...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | — | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | — | Undisclosed |